FluoGuide A/S (STO:FLUO)

Market Cap	678.50M +22.4%
Revenue (ttm)	318.79K -42.9%
Net Income	-57.18M
EPS	-4.07
Shares Out	16.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,883
Average Volume	4,660
Open	41.40
Previous Close	41.10
Day's Range	41.30 - 43.80
52-Week Range	28.00 - 47.60
Beta	0.42
RSI	50.39
Earnings Date	May 27, 2026

About FluoGuide

FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 7
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: FLUO

Financial Performance

In 2025, FluoGuide's revenue was 220,000, a decrease of -42.86% compared to the previous year's 385,000. Losses were -39.46 million, 36.3% more than in 2024.

Financial numbers in DKK